We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,500
Open access books available

108,000
International authors and editors

1.7 M
Downloads

151
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Percutaneous Pelvic Perfusion with Extracorporeal Chemofiltration for Advanced Uterine Cervical Carcinoma

Takeshi Maruo¹, Satoru Motoyama², Shinya Hamana³, Shigeki Yoshida⁴, Masashi Deguchi⁴, Mineo Yamasaki⁴ and Yanson Ku⁵

¹Kobe Children’s Hospital and Feto-Maternal Medical Center, Kobe
²Department of Obstetrics and Gynecology, Aijinkai Chibune General Hospital, Osaka
³Department of Obstetrics and Gynecology, Akashi Medical Center, Akashi
⁴Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe
⁵Department of Liver and Transplantation Surgery, Kobe University Graduate School of Medicine, Kobe Japan

1. Introduction

Advanced stages of uterine cervical cancer, especially those classified as stages IIIa to IVa, are unlikely treated with radical surgery alone. Intra-arterial infusion chemotherapy for advanced uterine cervical cancer has been shown to result in remarkable clinical outcomes as compared with those administered systemically (Panici et al. 1991, Vermorken 1993, Kigawa et al. 1996). Scarabelli and his colleagues (1987) described that the intra-arterial infusion as first-line chemotherapy for advanced uterine cervical carcinoma could deliver broadened options and improved radicality of the following conventional treatments such as surgery or radiotherapy, through the immediate tumor response despite the relative low adverse effects. On the contrary, Onishi and his colleagues (Onishi et al. 2000) reported that although intraarterial infusion achieved better local response compared to patients treated with radiotherapy alone, local recurrence and distant metastasis were inevitable in their study group. Studies by Eddy and his colleagues (1995) who used chemotherapy with bleomycin, vincristine, mitomycin and cisplatin followed by radiotherapy in patients with stage IIIb cervical cancer demonstrated a satisfactory response rate but with intolerable toxicity. On the other hand, patients who received intravenous infusion followed by radiotherapy had significantly inferior survival compared with those who received radiotherapy alone (Tattersall et al. 1995). The reason for such discrepancy in the results might be attributed to the insufficient local control of the tumor.

It is generally accepted that the dose escalation of chemotherapy was linked to improved tumor response (Levin and Hryniuk 1987, Levin et al. 1993). Currently, cisplatin has become one of the most effective oncostatics in gynecologic oncology and is believed to demonstrate a potential antitumor effect against squamous cell carcinoma of the cervix (Thigpen et al. 1981,
Neoadjuvant Chemotherapy – Current Applications in Clinical Practice

Ozol and Young 1984). However, higher antitumor effect has been generally accepted to be correlated with higher dose intensity but associated with severe toxicity. To reduce the dose-limiting toxicity and increase the antitumor effect, the authors developed super high-dose intra-arterial cisplatin infusion under percutaneous pelvic perfusion with extracorporeal chemofiltration (PPPEC) to achieve the ultimate use of cisplatin in the neoadjuvant setting for advanced cervical carcinoma (Hamana et al. 2001, Motoyama et al. 2001). The authors have shown that PPPEC system achieved a high-dose cisplatin pelvic perfusion with minimal adverse effects, permitting cisplatin dose escalation with further augmentation of the tumor response. Furthermore, high-dose intra-arterial infusion chemotherapy under PPPEC achieved a high frequency of rapid tumor shrinkage of locally advanced uterine cervical cancer with favorable performance of the subsequent radical surgery (Motoyama et al. 2004).

2. Procedures of percutaneous pelvic perfusion with extracorporeal chemofiltration

2.1 Intra-arterial infusion
Intra-arterial infusion catheters were inserted percutaneously in bilateral internal iliac arteries using Seldinger’s techniques via bilateral femoral arteries under fluoroscopic guidance. The tip of the catheter was located close to the uterine artery after ceramic-coil embolization of both superior and inferior gluteal arteries so as to deliver high concentrations of drug in the tumor lesion via the uterine arteries. The other tips of bilateral infusion catheters were connected to an infusion pump.

2.2 Extracorporeal chemofiltration system
For the first course of PPPEC, the right saphenofemoral junction was exposed through a small cut-down incision. Once vascular access established, an activating clotting time longer than 200 seconds was maintained with systemic heparinization. After anticoagulation, the specially designed inferior vena cava (IVC) occlusion balloon catheter (Radiopaque, 60 cm long, 21 French, with a single balloon and three lumens; Sumitomo Bake Corporation., Ohtsu, Japan.) (Ku et al. 1995) was introduced through the right femoral vein and was advanced under fluoroscopic guidance until the tip was beneath the renal vein. The balloon was then inflated with half-strength iodinated contrast at a rate of 4 ml to 6 ml. To determine whether isolation of the IVC was complete, contrast was injected through the drainage lumen under transient occlusion of IVC. Venography taken during this injection showed complete retrograde filling of the entire IVC and confirmed the absence of contrast leak over the isolation balloon (Figure 1). The distal ends of the IVC catheter were connected to the extracorporeal system, including the chemofilter cartridge containing active carbon beads (DHP-1; Kuraray Company, Ltd., Osaka, Japan) and a centrifugal pump (model BP-80; Biomedicus, Inc., Eden Prairie, MN, U.S.A.), as schematically illustrated in Figure 2.

The IVC blood through the balloon catheter was initially directed to the filter-excluded shunt (route A). After hemodynamic stability was verified, the direction of IVC blood flow was switched to the chemofiltration route (route B). After the PPPEC system had been accomplished, super high-dose cisplatin (140-250 mg/m2) alone or cisplatin plus an ordinal dose of pepleomycin (7 mg/m2), mitomycin C (7 mg/m2) and 5-fluorouracil (700 mg/m2) were administered during 30 minutes by dose allocation according to the difference in the bilateral vascularity of the uterine artery, as verified by the previous arteriogram.
Percutaneous Pelvic Perfusion with Extracorporeal Chemofiltration for Advanced Uterine Cervical Carcinoma

A. Complete IVC occlusion by catheter balloon. B. Absence of iodinated contrast leakage above the occluding balloon.

Fig. 1. Roentgenogram and venogram of inferior vena cava (IVC) isolation by catheter balloon.

After PPPEC, the hydration regimen was similar to that of the systemically administered cisplatin for the purpose of reducing renal toxicity. The second course of PPPEC was performed in the same manner via the left saphenofemoral junction, 2 weeks after the first course of PPPEC.

Fig. 2. Diagram of percutaneous pelvic perfusion with extracorporeal chemofiltration system. Tumor-perfusing blood was drained out in the extracorporeal circuit by a centrifugal pump via the drainage channel beneath the balloon in the catheter. After chemofiltration, the blood was directed into the IVC circulation again via the return channel over the balloon in the catheter. The chemofiltration cartridge (DHP-1) contains active carbon beads.

www.intechopen.com
3. Clinical examinations

3.1 Patients

Twenty-three patients admitted to Kobe University Hospital who had uterine cervical cancer stage IIIa to IVa according to the FIGO classification, were included in the present review. None of the patients had severe complications, such as diabetes mellitus, hypertension, renal failure or any other significant co-morbid conditions, and all had a World Health Organization (WHO) performance status (PS) score of 2 or less. All the patients had primary, untreated uterine cervical cancer. Prior to the study, patients were clinically staged based on pelvic examination, and several laboratory examinations, including intravenous pyelography, chest X-ray, cystoscopy, and routine serum chemistries, were performed. Metastasis was detected using a computerized tomography (CT) scan, whereas the localization and the size of cervical tumors were determined using magnetic resonance imaging (MRI) of the abdomen and pelvis.

During the same period of study, the authors had a total of 609 cervical cancer cases managed at our hospital. This includes 109 patients with locally advanced cervical cancer classified as stages IIIa, IIIb, or IVa. Among these 109 patients, 23 consented to PPPEC while the others received radiotherapy alone (17 patients) or conventional therapy (52 patients) consisting of palliative chemotherapy or cytoreductive surgery with or without radiotherapy. Radiotherapy was administered as follows: irradiation to the whole pelvis was 50.4 Gy, center split at 20 Gy, and vaginal vault at 18 Gy.

The mean age of the patients was 56.2±12.0 years. The mean diameter of the cervical tumor was 4.9±1.8 cm. The PS of all patients was zero. Based on FIGO clinical staging, 1 patient was classified as having stage IIIa cancer, 17 patients as having stage IIIb cancer, and 5 patients as having stage IVa cancer. Histologic types included 21 squamous cell carcinoma, 1 adenocarcinoma, and 1 adenosquamous carcinoma. Patients’ characteristics are summarized in Table 1.

<table>
<thead>
<tr>
<th>Age</th>
<th>56.2 ±12.0 y (range: 27-68 y)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean diameter of cervical tumor</td>
<td>4.9 ±1.8 cm (range: 4.5 – 12.0 cm)</td>
</tr>
<tr>
<td>Performance status (based on WHO)</td>
<td>0</td>
</tr>
<tr>
<td>FIGO clinical stage (no. of patients)</td>
<td></td>
</tr>
<tr>
<td>IIIa</td>
<td>1</td>
</tr>
<tr>
<td>IIIb</td>
<td>17</td>
</tr>
<tr>
<td>IVa</td>
<td>5</td>
</tr>
<tr>
<td>Histologic type (no. of patients)</td>
<td></td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>21</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>1</td>
</tr>
<tr>
<td>Adenosquamous carcinoma</td>
<td>1</td>
</tr>
</tbody>
</table>

Table 1. Patients’ characteristics
Serial blood samples were obtained from prefilter, postfilter, and peripheral blood (radial artery) after the start of cisplatin infusion. Tissue samples were obtained by colposcopic punch biopsies from cervical lesion after the first course of PPPEC and by radical surgery 2 weeks after the second course of PPPEC. Plasma and tissue platinum concentrations were measured by flameless atomic absorption spectrometry (Pera et al. 1979).

3.2 Pharmacokinetics of free platinum in extracorporeal chemofiltration circuit
The time course of mean plasma free-platinum (f-Pt) concentration (n = 3) at each prefilter, postfilter, and peripheral site with various cisplatin doses is shown in Figure 3. The peak plasma concentration (maximum concentration, C_max) was noted to be 20 to 30 minutes in each time course, but most of them decayed to less than 1.0 µg/ml at 50 minutes after initiation of the infusion. This is indicative that although the prefilter mean f-Pt C_max levels increased in a cisplatin dose-dependent manner (range: 7.2—12.2 µg/ml), the postfilter and peripheral f-Pt C_max levels were all in the low range (postfilter range: 2.1—3.6 µg/ml; peripheral range: 1.0—3.8 µg/ml).

140 mg/m² (open circle with dashed line), 170 mg/m² (closed circle with dashed line), 200 mg/m² (open circle with solid line), 240 mg/m² (closed circle with solid line).

Fig. 3. Dynamics of plasma free-platinum concentrations at different sites.

3.3 Comparison in pharmacokinetics and tumor response between PPPEC and conventional arterial infusion (CAI)
The pharmacokinetic study comparing peripheral plasma f-Pt concentrations and area under the concentration–time curve between PPPEC and conventional arterial infusion (CAI) demonstrated that f-Pt C_max was 2.1 ± 0.1 µg/ml in PPPEC with cisplatin at a dose of 140 mg/m². This was only a 33% increase in the C_max relative to that in CAI (1.5 ± 0.2 µg/ml) with cisplatin at a dose of 70 mg/m², and a 12% increase in the mean area under the
concentration–time curve as compared with that in CAI (Figure 4). Conversely, the tumor response rate evaluated after completion of two courses of PPPEC was verified to increase remarkably from 44% with a 70 mg/m² cisplatin course to 100% with a 140 mg/m² cisplatin course according to cisplatin dose escalation.

The arrow shows each Cmax. PPPEC, percutaneous pelvic perfusion with extracorporeal chemofiltration; super high-dose intra-arterial cisplatin infusion under percutaneous pelvic perfusion with extracorporeal chemofiltration; CAI, conventional arterial infusion.

Fig. 4. Time course of plasma free-platinum concentrations in peripheral circulation.

### 3.4 Tissue-platinum concentrations

The mean tissue Pt concentrations obtained by cervical lesion biopsies at 12 hours and 24 hours after the first course of PPPEC are shown in Figure 5A. A dose-dependent increase in the mean tissue Pt concentration was noted. Particularly, the value (18.6 µg/wet · g) in tumor tissue specimens obtained at 24 hours after the first course of PPPEC with cisplatin at a dose of 200 mg/m² cisplatin was remarkably higher compared with that with lower doses of cisplatin and with that obtained at 12 hours after PPPEC with the same dose of cisplatin. On the other hand, Figure 5B represents the mean tissue Pt concentration in resected common iliac lymph nodes and cervical tumor tissues obtained by radical surgery. The increase in Pt concentrations in the resected lymph nodes and cervical tumor tissues was distinct, depending on cisplatin dose escalation.
Percutaneous Pelvic Perfusion with Extracorporeal Chemofiltration for Advanced Uterine Cervical Carcinoma

Fig. 5. Tissue platinum concentrations in cervical tumor lesions and resected lymph nodes. Each bar shows the mean tissue Pt concentration in the cervical tumor tissues obtained by biopsies at 12 h and 24 h after the first course of PPPEC (a), and in the surgical specimens and resected common iliac lymph nodes obtained by radical hysterectomy 2 weeks after the second course of PPPEC (b).

3.5 Adverse effects

There was little renal impairment, gastrointestinal toxicity, myelosuppression, and alopecia. Neither neurogenic nor auditory alteration was detected. The other adverse effects connected with PPPEC were mild anemia caused by blood retention in the circuit (~200–300 ml) and hemolysis resulting from destruction by resistance in the circuit. All the adverse effects were less than grade II (Table 2). There were no critical catheter complications in the present study.

<table>
<thead>
<tr>
<th>Adverse effects</th>
<th>No. of patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPPEC related</td>
<td></td>
</tr>
<tr>
<td>Hemolysis/hematuria</td>
<td>0</td>
</tr>
<tr>
<td>Thrombocytopenia &lt; 5 x 10^4/mm³</td>
<td>3 (21.4)</td>
</tr>
<tr>
<td>Bleeding</td>
<td>0</td>
</tr>
<tr>
<td>Cisplatin related</td>
<td></td>
</tr>
<tr>
<td>Leukopenia &lt; 2,000/mm³</td>
<td>2 (14.3)</td>
</tr>
<tr>
<td>Creatinine &gt; 1.5 mg/dl</td>
<td>2 (14.3)</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>3 (21.4)</td>
</tr>
<tr>
<td>Alopecia</td>
<td>0</td>
</tr>
</tbody>
</table>

Table 2. Adverse Effects Assessment for PPPEC
3.6 Clinical response

In order to evaluate the tumor response, the volumetric reduction of cervical tumors was calculated by multiplying three spatial axes based on MRI examination. Tumor response was designated as complete response (CR), partial response (PR), minor response (MR) or no response (NR), as previously described (Minagawa et al. 1998). On the other hand, tumor downstaging and clinical response in the vagina, urinary bladder and parametrium were evaluated by colposcopic punch biopsy, cystoscopic examination, drip infusion pyelography, MRI, and gynecologic examination. Tumor downstaging or positive tumor response was considered when the cancer cells in the lesion disappeared or when there was evidence of reduction of parametrial involvement.

The mean volumetric reduction rate was 76% (range: 50.0-100%). The tumor response rate evaluated after the second PPPEC were 13% for CR and 74% for PR. The overall tumor response (CR + PR) was 87%. Histopathological effects on the surgical specimens revealed 4% for grade I, 83% for grade II, and 13% for grade III. Tumor downstaging, based on the tumor response and the histologic response reached 83% after the second PPPEC (Table 3).

<table>
<thead>
<tr>
<th>Tumor reduction % (range)</th>
<th>76 % (range: 50.0-100%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor response % (no. of patients)</td>
<td></td>
</tr>
<tr>
<td>CR</td>
<td>13% (3 out of 23 patients)</td>
</tr>
<tr>
<td>PR</td>
<td>74% (17 out of 23 patients)</td>
</tr>
<tr>
<td>MR + NC</td>
<td>13%</td>
</tr>
<tr>
<td>Histologic effects % (no. of patients)</td>
<td></td>
</tr>
<tr>
<td>G1</td>
<td>4% (1 out of 23 patients)</td>
</tr>
<tr>
<td>G2</td>
<td>83% (19 out of 23 patients)</td>
</tr>
<tr>
<td>G3</td>
<td>13% (3 patients)</td>
</tr>
<tr>
<td>Overall histologic effects</td>
<td>96% (22 out of 23 patients)</td>
</tr>
<tr>
<td>Tumor down-staging % (no. of patients)</td>
<td>83% (19 patients)</td>
</tr>
</tbody>
</table>

CR, complete response; PR, partial response; MR, minor response; NC, no change

Table 3. Tumor Response after PPPEC

3.7 Surgical performance

Radical surgery was performed on 18 of the 23 patients who had confirmed tumor downstaging. The radical surgery performance rate was 78%. The remaining 5 patients, who had insufficient stage regression (4 cases) and a poor PS despite tumor downstaging (1 case), received radiotherapy. Review of the surgical specimens revealed that 16 of the 18 surgical patients had negative surgical margins, leading to a curative surgery rate of 89%.

Response rate of the involved lesions other than the cervical tumor evaluated after the second PPPEC revealed 89% for the parametrium, 94% for the vagina, and 100% for the urinary bladder. Lymph node metastasis was detected in 9 of the surgical patients and an overall histologic effect in these metastases was 56% (Table 4).
Percutaneous Pelvic Perfusion with Extracorporeal Chemofiltration for Advanced Uterine Cervical Carcinoma

Parameter | Rate in % (no. of patients) |  
--- | --- |  
Radical surgery | 89 % (18 out of 23 patients) |  
Curative surgery | 89 % (16 out of 18 patients) |  
Radiotherapy | 22% (5 out of 23 patients) |  
Lesion response |  
Parametrium | 89 % (16 out of 18 patients) |  
Vagina | 94 % (17 out of 18 patients) |  
Urinary bladder | 100 % (5 out of 5 patients) |  
Lymph node metastases | 50 % (9 out of 18 patients) |  
G3 | 0 % |  
G2 | 28 % (5 patients) |  
G1 | 22 % (4 patients) |  
Overall histologic effects | 56 % |  

Table 4. Evaluation of radical surgery and surgical specimens after PPPEC

4. Treatment after percutaneous pelvic perfusion with extracorporeal chemofiltration (PPPEC)

Following PPPEC, class III radical hysterectomy based on Rutledge classification was performed on patients who demonstrated tumor downstaging according to FIGO classification. Radiotherapy was used in patients uncertain for the tumor downstaging or with a poor PS. Adjuvant radiotherapy on the surgical cases was determined based on the histopathologic diagnosis of the surgical specimens. Patients who had pelvic, common iliac or periaortic lymph node metastasis were subjected to periaortic radiation of 40 Gy aside from the whole pelvic and vaginal vault radiation of 18 Gy in patients who had stage IIIa cancer after the second course of PPPEC.

4.1 Clinical outcomes of stage IVa patients

As shown in Table 5, five patients who had confirmed stage IVa cancer with bladder invasion had squamous cell carcinoma. One patient had CR while the other four had PR. All

<table>
<thead>
<tr>
<th>Case number</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor size (mm)</td>
<td>32</td>
<td>61</td>
<td>28</td>
<td>63</td>
<td>63</td>
</tr>
<tr>
<td>Tumor response</td>
<td>PR</td>
<td>PR</td>
<td>CR</td>
<td>PR</td>
<td>PR</td>
</tr>
<tr>
<td>Downstaging</td>
<td>Ib</td>
<td>Ib</td>
<td>&lt;Ib</td>
<td>IIb</td>
<td>IIIb</td>
</tr>
<tr>
<td>Surgery</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Surgical margin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>NA</td>
</tr>
<tr>
<td>Lymph node metastases</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>NA</td>
</tr>
<tr>
<td>Recurrence (months after PPPEC)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>11</td>
<td>13</td>
</tr>
<tr>
<td>Current status</td>
<td>NED</td>
<td>NED</td>
<td>NED</td>
<td>DOD</td>
<td>DOD</td>
</tr>
</tbody>
</table>

NA, not applicable; NED, no evidence of disease; DOD, died of disease

Table 5. Characteristics of stage IVa patients and their clinical response after PPPEC
the stage IVa patients had tumor downstaging. Four patients underwent a class III radical hysterectomy with resultant curative surgery. Three patients had lymph node metastasis and two patients had a recurrence.

4.2 Analysis of recurrent cases
Recurrence was detected in 10 patients (Table 6). Adjuvant therapy administered to these patients consisted of radiotherapy and chemotherapy to those who underwent radical surgery, while chemotherapy was delivered to the rest. The initial stages of the 10 cases were as follows: 8 stage IIIb cancer and 2 stage IVa cancer. Nine of the 10 patients demonstrated lymph node metastasis. The mean time to recurrence was 13.8 months (range: 4-32 months).

<table>
<thead>
<tr>
<th>Parameters</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell type</td>
<td>SCC</td>
<td>SCC</td>
<td>SCC</td>
<td>SCC</td>
<td>A</td>
<td>SCC</td>
<td>SCC</td>
<td>SCC</td>
<td>SCC</td>
<td>SCC</td>
</tr>
<tr>
<td>Surgery</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>S. margins</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>NA</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>LN mets</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Adj therapy</td>
<td>RCT</td>
<td>RCT</td>
<td>RCT</td>
<td>CT</td>
<td>RCT</td>
<td>RCT</td>
<td>RCT</td>
<td>CT</td>
<td>CT</td>
<td>CT</td>
</tr>
<tr>
<td>Rec sites</td>
<td>l</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>p</td>
<td>ud</td>
<td>ud</td>
<td>p</td>
<td>p</td>
<td>p</td>
</tr>
<tr>
<td>Rec (months)</td>
<td>16</td>
<td>12</td>
<td>11</td>
<td>8</td>
<td>13</td>
<td>10</td>
<td>11</td>
<td>32</td>
<td>4</td>
<td>11</td>
</tr>
</tbody>
</table>

A, adenocarcinoma; Adj therapy, adjuvant therapy; CT, chemotherapy; l, lungs; LN mets, lymph node metastases; NA, not applicable; p, pelvis; RCT, radiotherapy and chemotherapy; Rec (months), evidence of recurrence in months after PPPEC; Rec sites, areas of recurrence; SCC, squamous cell carcinoma; ud, undetectable.

Table 6. Evaluation of recurrent cases

4.3 Evaluation of survival
As far as the survival of the patients who received two courses of PPPEC is concerned, the 5-year progression-free survival was similar among those who underwent radical surgery (47%) and those who underwent radiotherapy (50%) after PPPEC. The 5-year progression-free survival (47%) in the PPPEC group was higher to that of patients who received radiotherapy alone (28%) at the authors institution (Kobe University Hospital). Furthermore, patients who received PPPEC showed an improvement in the 5-year survival rate (74%) compared with that of a similar patient group who received radiotherapy alone at our hospital (58%) or those who received conventional therapy, which includes those who had palliative chemotherapy or cytoreductive surgery with or without radiotherapy (43%) (Figure 6).
Fig. 6. Survival rate of patients comparing the different treatments at authors’ institution. Patients who received PPPEC showed an improvement of the 5-year survival rate (74%) compared with that of similar patient group who received radiotherapy alone (58%) or those who received conventional therapy (43%). Survival was compared by the Kaplan-Meier method.

5. Discussion

The use of PPPEC demonstrated a significant increase in tissue Pt-concentrations in patients receiving at a dose of 200 mg/m² cisplatin at a time or more than 400 mg/m² cisplatin in total compared with those receiving cisplatin at a dose of 140 mg/m² at a time or 280 mg/m² cisplatin in total. It might be crucial for tumor cell kill that high intratumoral tissue Pt concentrations must be achieved throughout the entire tumor. Providing insight into this concept, the dose allocation of cisplatin administered in PPPEC was decided according to the vascular disparity among bilateral uterine arteries (Kohno et al. 1993). Because of the high reduction rate of f-Pt by DHP-1 filters, the amount of f-Pt passing into the peripheral circulation was remarkably decreased; therefore, the dose-limiting toxicities, especially nephrotoxicity, were limited and tolerated.

The mean tissue Pt concentration in common iliac lymph nodes after administration of cisplatin at a dose of 400 mg/m² was 7.4 µg/wet · g, which was higher than the minimal concentration (3.4 µg/wet · g) for tumor cell kill (Jaffe et al. 1983), but was lower than the satisfactory concentration (17.0 µg/wet · g) for total tumor cell kill. This may be responsible for the ineffective control of lymph node metastases. Because tissue Pt concentrations in pelvic lymph nodes correlated with the distance from the cervix, it seems that antitumor effect in the pelvic lymph nodes, particularly distant lymph nodes, such as common iliac and para-aortic nodes, may be inferior to that in cervical tumor lesions.

In this review, the results of 23 patients with an initial diagnosis of uterine cervical cancer stage IIIa to IVa treated with high-dose cisplatin or high-dose cisplatin plus ordinal doses of
popleomycin, mitomycin C and 5-fluorouracil administered in two courses at a 2-week interval by means of PPPEC were presented. The reduction of extensive parametrial involvement and complete regression of bladder invasion after the second course of PPPEC made radical hysterectomy possible in these patients. After the performance of PPPEC, radical surgery or radiotherapy were performed. In advanced stages of uterine cervical cancer, radical hysterectomy is generally associated with surgical difficulties; hence, the use of vessel-sealing system, electrocautery system or argon beam coagulation is advocated. Therefore, the prognosis of patients who have stage IIIb or IVa uterine cervical cancer based on the present therapeutic strategy with PPPEC was better compared with that of conventional therapy. Our findings were congruent to published reports demonstrating that the use of intra-arterial infusion was beneficial to patients with advanced uterine cervical cancer (Minegawa et al. 1998, Sugiyama et al. 1998, Fujiwaki et al. 1999, Nagata et al. 2000). The existence of lymph node metastasis is a poor prognostic factor in patients with cervical cancer (Terada et al. 1988, Tinga et al. 1992). Patients with locally advanced uterine cervical cancer have a high incidence of lymph node metastasis. In the patients treated with PPPEC, the rate of overall histologic effects in metastatic lymph nodes barely reached 56%, a value which was less compared with the overall histologic effects in the cervical tumor (96%). This could be attributed to the decline in the chemodrug concentrations at areas distant from the infusion site. Intra-arterial infusion chemotherapy might have less antitumor effect in the pelvic lymph nodes than in the cervical tumor lesions. In order to improve the long-term prognosis of locally advanced uterine cervical cancer, it is necessary to increase tumoricidal chemodrug concentrations in periaortic lymph nodes, or the pelvic lymph nodes at least (Burke et al. 1987). To achieve a satisfactory antitumor effect in periaortic lymph nodes, higher doses of cisplatin, an effective combination with other oncostatic agents, or a novel drug delivery system will be required (Park et al. 1995, Leone et al. 1996).

Up to the present time, with 63 months of median follow-up time, the 5-year survival rate for patients treated with PPPEC is superior to that of patients who received the conventional mode of treatment consisting of palliative surgery or chemotherapy and radiotherapy at the authors’ institution (Kobe University Hospital, Kobe, Japan). Furthermore, the 5-year progression-free survival and 5-year survival in the PPPEC group are higher than those of patients who received radiotherapy alone at authors’ institution. This prompted the authors to use the PPPEC system in the management of patients who have locally advanced uterine cervical cancer. Although the 5-year progression free survival in those patients who received radical surgery or radiation therapy after PPPEC is similar, several clinical and pathological factors have been implicated to be of prognostic significance as far as progression-free survival and prognosis are concerned. These are as follows: Gynecologic Oncology Group PS (0-2), tumor size, tumor growth pattern (exophytic vs. barrel), histologic type, tumor grade and age at study entry (Key et al. 2003). Further research should be directed to the identification of suitable chemotherapeutic agents, defining clinical indications, and development of technical modification to make it more generally applicable.

6. Conclusion

The clinical results described in the present review suggest that PPPEC has a therapeutic advantage because of prompt tumor downstaging of locally advanced uterine cervical cancer with minimal adverse effects, thereby facilitating more options and radicality of the subsequent main therapy. This further leads to an improvement of the long-term survival
for patients with locally advanced uterine cervical cancer. A prospective randomized trial will clarify the optimal mode of initial therapy for patients with stages IIIa - IVa uterine cervical cancer.

7. Acknowledgment

The authors would like to thank the staff members of the Department of Liver and Transplantation Surgery of Kobe University Graduate School of Medicine, Kobe, Japan for their dedicated collaboration to establish the PPPEC system for advanced uterine cervical cancer. This study was supported by the Grant-in-Aid for Scientific Research 15390506 from the Japanese Ministry of Education, Culture, Sports, Science and Technology.

8. References


The most significant advances in cancer therapy in recent years have involved the development of systemic therapeutics. With improvements in response rates in solid tumors, opportunities have arisen to enhance the effectiveness of surgery. Administration of systemic therapy prior to surgery - neoadjuvant chemotherapy - represents one approach by which clinicians have successfully reduced the extent of surgery and, in some instances, positively impacted on clinical outcomes. This collection of works by expert clinicians from a variety of disciplines represents an exploration of the current knowledge of the role of neoadjuvant chemotherapy in diverse tumor types.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:


InTech Europe
University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都饭店办公楼405单元
Phone: +86-21-62489620
Fax: +86-21-62489821